Immunomodulatory and Anticancer Activities of Enterocin Oe-342 Produced by Enterococcus Feacalis Isolated from Stool

Objectives: This study evaluated the anticancer activity of Entr. faecalis enterocin OE-342 by testing its direct antitumor effects on colorectal cancer cell line, as well as, its immunomodulatory effects. Methods: The anticancer potentiality of this enterocin against human colorectal adenocarcinoma (HCT-116) cells was evaluated using cytotoxicity, cell cycle analysis, apoptosis and monitoring morphological changes of the treated cells. Also the immunomodulatory effects of the tested enterocin were quantified on LPS-induced PBMCs cell model with monitoring TNF-α and IFNγ levels using flowcytometry. Results: The obtained data showed that enterocin OE342 inhibited HCT-116 cellular viability in a concentration dependant manner with somewhat high IC50 value recording 49.920 mg/ml. Upon HCT-116 treatment with this enterocin the appearance of undergoing apoptotic cells characterized by cellular rounding up, shrinkage and membrane blebbing was observed. Cytotoxicity of enterocin OE-342 was accompanied by cell cycle arrest in the G2/M phase (24.66%) accompanied with an increase in the ratio of the apoptotic cells in the preG1cell cycle phase. Also, this enterocin affected the generation of TNF-α and IFNγ from LPS-induced PBMCs cell resulting in inhibition of the first by 27.3% and induction of the second by 69.5% which suggest the immunomodulatory effects of the tested enterocin. Conclusion: Taken together, our results suggest the anticancer potentialities of enterocin OE-342 against human colon cancer cells represented through its effects on both apoptotic and inflammatory pathways.